Recent advances in small molecule inhibitors of interleukin‑1 receptor-associated kinase / 药学学报
Acta Pharmaceutica Sinica
; (12): 27-38, 2023.
Article
in Zh
| WPRIM
| ID: wpr-964296
Responsible library:
WPRO
ABSTRACT
Interleukin-1 receptor associated kinase 4 (IRAK-4), acting as a serine threonine kinase, is considered as a key signal node for the transduction of IL-1R family and TLRs signal pathway. Studies have found that IRAK-4 has a hand in many signal pathways, involving the inflammatory response of human joints, intestines, liver and nervous system, as well as other autoimmune diseases. It is also one of the causes of drug resistance of some cancer cells. Therefore, IRAK-4 tends to be an effective therapeutic target for inflammatory diseases and cancer. The prospects for the development of drugs in this pathway is to develop novel IRAK-4 small molecule inhibitors and investigate their safety and effectiveness, enrich the clinical treatment of inflammatory and cancer diseases finally. This paper classified and summarized the latest research progress on small molecule inhibitors of IRAK-4 signaling pathway according to structures of the compounds, in order to provide assistances and references for the research and development of related drugs.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Acta Pharmaceutica Sinica
Year:
2023
Type:
Article